2016 International Congress Archives - Page 41 of 207

12:00pm-1:30pm: Reliability of the sensory organization test to predict falls in individuals with Parkinson’s disease

T.E. Apoznanski, S. Yao, M.K. Jung, J. DiFrancisco-Donoghue (Old Westbury, NY, USA)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Results of the German registry of pediatric deep brain stimulation in patients with childhood-onset dyskinetic movement disorders (GEPESTIM)

A. Koy, W. Milena, K.A.M. Pauls, A.A. Kühn, P. Krause, J. Hübl, G.H. Schneider, G. Deuschl, R. Erasmi, D. Falk, J.K. Krauss, G. Lütjens, A. Schnitzler, L. Wojtecki, J. Vesper, R. Korinthenberg, V.A. Coenen, V. Visser-Vandewalle, M. Hellmich, L. Timmermann (Cologne, Germany)

Pediatric movement disorder · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Risk factors associated with postural changes in Parkinson’s disease

A. Khlebtovsky, O. Keret, Y. Rodity, G. Tsvetov, I. Slutzcki-Shraga, F. Benninger, R. Djaldetti (Petach Tikva, Israel)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Risk factors for premature withdraw from the LS-1 PD study

J.Y. Fang, S. Luo, M. Huang, R.B. Dewey, R. Hauser, G. Chen (Nashville, TN, USA)

Clinical trials and therapy in movement disorders · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Robust sensorimotor deficits in a knock-in mouse model of primary torsion dystonia

F. Richter, J. Gerstenberger, A. Bauer, C. Helmschrodt, A. Richter (Leipzig, Germany)

Dystonia · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia

G. Gangarossa, M. Guzman, V. Prado, M. Prado, S. Daumas, S. El Mestikawy, E. Valjent (Paris, France)

Pharmacology

12:00pm-1:30pm: Role of the nurse coordinator within a unit for treatment of neuro-surgical behaviours and abnormal movements

E. Borgeais, C. Fournera, I. Creff, P. Coubes (Montpellier, France)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Rotigotine transdermal patch in Chinese patients with advanced Parkinson’s disease: A randomized, double-blind study

Z. Zhang, M. Asgharnejad, H. Xue, E. Surmann, L. Bauer (Beijing, People's Republic of China)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up

B.J. Snow, E. Mulroy, M. Simpson, L. Macdonald, A. Bok, K. Taylor, J. Han, K. Durbin (Auckland, New Zealand)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis

N. Elsagheer, H. Ahmed, A. Attia, K. Awad, E. Ezzat, M. Abd Elaleem Aziz, A. Negida (Beni Suef, Egypt)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2